Publication Name	World Journal of Psychiatry
Manuscript ID	71664
Country	Kuwait

Received	2021-09-16 20:14
Peer-Review Started	2021-09-16 20:15
To Make the First Decision
Return for Revision	2021-11-08 03:36
Revised	2021-11-08 18:05
Second Decision	2022-02-11 05:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-13 17:03
Articles in Press	2022-02-13 17:03
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-02-09 16:30
Typeset the Manuscript	2022-03-09 02:00
Publish the Manuscript Online	2022-03-18 12:26

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Letter to the Editor
Article Title	Therapeutic use of melatonin in schizophrenia-more than meets the eye!
Manuscript Source	Invited Manuscript
All Author List	Ahmed Naguy
ORCID	Author(s) ORCID Number Ahmed Naguy http://orcid.org/0000-0002-6465-456X
Funding Agency and Grant Number
Corresponding Author	Ahmed Naguy, MBChB, MSc, Staff Physician, Al-Manara CAP Centre, Kuwait Centre for Mental health (KCMH), Jamal Abdul-Nassir Street, Shuwaikh 22094, Kuwait. ahmednagy@hotmail.co.uk
Key Words	Melatonin; Schizophrenia; Chronobiotic; Neuroprotectant; Antipsychotic; Tardive dyskinesia; Metabolic syndrome
Core Tip	Adjuventia Melatonin use in schizophrenia is strongly recommended. This is supported by a modicum of evidence base. Use is multi-folded transcending chronobiotic actions, rectifying sleep disturbance in schizophrenia, to bona fide augmentative antipsychotic actions, mitigating the risk of relentless tardive dyskinesias, curbing the drastic cardio-metabolic syndrome and ultimately neuroprotective actions in the face of neuroprogressive course of schizophrenia over time.
Publish Date	2022-03-18 12:26
Citation	Naguy A. Therapeutic use of melatonin in schizophrenia-more than meets the eye!. World J Psychiatry 2022; 12(3): 533-535
URL	https://www.wjgnet.com/2220-3206/full/v12/i3/533.htm
DOI	https://dx.doi.org/10.5498/wjp.v12.i3.533

Full Article (PDF)	WJP-12-533.pdf
Full Article (Word)	WJP-12-533.docx
Manuscript File	71664_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	71664-Answering reviewers.pdf
Audio Core Tip	71664-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	71664-Conflict-of-interest statement.pdf
Copyright License Agreement	71664-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	71664-Language certificate.pdf
Peer-review Report	71664-Peer-review(s).pdf
Scientific Misconduct Check	71664-Bing-Fan JR-2.png
Scientific Editor Work List	71664-Scientific editor work list.pdf
CrossCheck Report	71664-CrossCheck report.pdf
CrossCheck Report	71664-CrossCheck.png